Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.
The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...
According to a release issued on January 6, 2026, the Nims blood bank recorded a landmark performance in voluntary blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback